Novartis delivers 35% ROE, 24% net margins, and a positive MACD breakout setup, but revenue declined 1% year-over-year, debt-to-equity is elevated at 1.2, the yield payout is flagged as unsafe, and consecutive earnings misses raise near-term execution concerns.
Thesis pillars
- Strong Margins And Roe→Stable
- Leverage Penalty Debt Risk↓Deteriorating
- Technical Breakout Above 200 Ma↑Improving
- +1 more pillar — see the Why tab for full reasoning
Novartis AG (NVS) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $152.32 — A.R:R is negative (-2.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.2): -0.5.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection... Read more
Sell if holding. Analyst target reached at $152.32 — A.R:R is negative (-2.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.2): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-08-12Recent Developments — Novartis AG
Latest news
- NEWS Novartis (NVS) Stock Drops 2% After Q1 Revenue Miss and Entresto Sales Plunge 42% - MEXC Exchange — MEXC Exchange negative
- NEWS Evergreen Capital Management LLC Has $6.51 Million Stock Position in Novartis AG $NVS - MarketBeat — MarketBeat positive
- NEWS UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail — The Globe and Mail neutral
- NEWS Novartis: Revenue Lags In Q1, Outlook Unchanged (NYSE:NVS) - Seeking Alpha — Seeking Alpha negative
- NEWS Novartis Stock Declines After Q1 Revenue Misses Expectations - GuruFocus — GuruFocus negative
Generated 2026-08-12T21:52:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $152.32 — A.R:R is negative (-2.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.2): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $147.04. Score 4.8/10, moderate confidence.
Take-profit target: $157.13 (-11.3% upside). Prior stop was $147.04. Stop-loss: $147.04.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.2): -0.5; Weak overall score: 4.8/10.
Novartis AG trades at a P/E of 23.7 (forward 15.7). TrendMatrix value score: 4.9/10. Verdict: Sell.
34 analysts cover NVS with a consensus score of 3.5/5. Average price target: $155.
What does Novartis AG do?Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland...
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.